
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies is well-positioned for continued success due to their strong financials, strategic partnerships and successful pricing negotiations in the heme market. With a successful first quarter in 1Q26 and a successful strategy with multiple growth drivers, ADPT is expected to continue to experience strong revenue and volume growth in the future. Additionally, ADPT's strong financial outlook and raised projections further indicate their positive trajectory and potential for continued success in the biotech industry.
Bears say
Adaptive Biotechnologies is a company with strong potential in the growing field of immune-driven medicine, as seen through its FDA-approved diagnostic product, clonoSEQ, and its promising Immune Medicine platform. However, the company's financials show significant losses since inception and a reliance on milestone payments for its MRD segment, potentially suggesting a lack of sustainability or profitability. Furthermore, despite strong quarterly results, the stock has underperformed this year and faces potential risks such as slower customer adoption and reimbursement challenges. With a current premium valuation, there may be limited room for further upside in the stock price.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares